Fennec Pharmaceuticals Announces Positive PEDMARK® Clinical Data at ASCO, Expanding Use to AYA and Adult Patients

summarizeSummary

Fennec Pharmaceuticals announced new research at the ASCO Annual Meeting, detailing positive clinical data for PEDMARK® in adolescent, young adult, and adult patient populations, expanding its potential utility beyond its current pediatric indication.

check_boxKey Events

• Positive Clinical Data for PEDMARK®

  New research presented at the ASCO Annual Meeting details PEDMARK®'s efficacy in reducing cisplatin-induced ototoxicity in adolescent, young adult, and adult patient populations.

• Phase 2/3 Trial Met Primary Endpoint

  Detailed results from the investigator-initiated Phase 2/3 STS-J01 clinical trial in Japan showed a significant reduction in hearing loss (16-24% vs. 56-63% historically) in 3-18 year-old patients.

• Expanded Clinical Utility

  Real-world evidence supports the feasible incorporation of PEDMARK® into AYA and adult oncology workflows without compromising cisplatin's antitumor activity, including in head and neck cancer patients.

• Addressing Unmet Need

  The studies highlight PEDMARK®'s potential to impact patient care more broadly by addressing permanent hearing loss, a major survivorship issue in oncology.

auto_awesomeAnalysis

This filing provides significant positive clinical updates for Fennec's key product, PEDMARK®. The detailed results from four independent studies, including a Phase 2/3 trial in Japan, demonstrate PEDMARK®'s efficacy in reducing cisplatin-induced hearing loss in broader patient groups (AYA and adults). This expands the potential market and clinical utility of the drug, reinforcing its value proposition and addressing a critical unmet need in oncology survivorship.